Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio exhibits a general downward trend over the analyzed periods. Starting at a high of 12.09 in the second quarter of 2019, it declines significantly through 2020 and 2021, reaching a low point of 0.4 in the third quarter of 2021. Some recovery is noted in late 2021 and 2022, but the ratio remains below initial levels, fluctuating around 1.0 towards the end of 2022 and early 2023. The most recent quarters show further declines, falling to 0.1 or below by the third quarter of 2023.
- Net Fixed Asset Turnover (Including Operating Lease, Right-of-Use Asset)
- This version of the net fixed asset turnover ratio follows a similar declining trend but shows generally lower values compared to the traditional net fixed asset turnover, reflecting the inclusion of operating lease assets. The ratio falls from 12.09 in early 2019 to below 1.0 by late 2020 and remains mostly below 1.0 through 2022 and 2023, with a low point of 0.05 in the third quarter of 2023. This suggests a consistent decrease in asset utilization efficiency when considering leased assets.
- Total Asset Turnover
- The total asset turnover ratio shows limited variability and remains relatively low across all periods. It starts around 0.17-0.18 in early 2019 and generally trends downward or stays flat in subsequent quarters. Notable dips occur towards late 2019 and again in the third quarter of 2021, dropping to as low as 0.03. Some recovery is seen in mid-2022 to early 2023, peaking at 0.2, but the ratio declines again sharply to approximately 0.01 by the third quarter of 2023. Overall, the efficiency in generating revenue from total assets remains minimal and volatile.
- Equity Turnover
- Equity turnover data is sporadic and incomplete, limiting trend analysis. Available data shows some increase from 0.36 in the third quarter of 2020 to 3.51 in the third quarter of 2021, followed by fluctuating levels around 0.09 to 1.36 in late 2021 and early 2022. After this period, data is missing, making it difficult to establish consistent patterns or trends for equity turnover beyond early 2022.
Net Fixed Asset Turnover
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Net fixed asset turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Fixed Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues exhibited a generally declining trend from early 2019 through mid-2020, dropping from a high of 8,464 thousand USD in March 2019 to a low point of 3,593 thousand USD in June 2020. This period is marked by notable volatility, including an anomalous spike to 41,688 thousand USD in September 2020 and another significant surge to 55,600 thousand USD in December 2021. However, these spikes appear isolated, with revenues dropping sharply again after these quarters. More recently, revenues have decreased substantially, reaching as low as 378 thousand USD in September 2023.
- Property and Equipment, Net
- There is a consistent and substantial upward trend in net property and equipment values over the entire period. The asset base almost doubled between March 2019 (3,175 thousand USD) and March 2021 (23,198 thousand USD) and continued to grow rapidly thereafter, peaking at 80,453 thousand USD in December 2022. A slight decline is observed in the quarters following December 2022, ending at 75,614 thousand USD in September 2023, but the overall direction remains strongly positive.
- Net Fixed Asset Turnover Ratio
- The net fixed asset turnover ratio has declined markedly throughout the reported periods. Starting at relatively high levels of above 10 in early 2019, this ratio fell steadily to below 1.0 by late 2021, signifying a decreasing efficiency in generating revenues from the fixed asset base. The ratio continues to hover near or below 1.0 through 2023, with extremely low values recorded in mid to late 2023 (0.13 and 0.1), indicating a diminishing ability to leverage fixed assets to produce sales.
- Overall Insights
- The financial data reveal a company expanding its fixed asset base aggressively while experiencing significant challenges in maintaining stable revenue streams. The repeated substantial revenue spikes suggest episodic events or transactions that temporarily inflate sales figures. The persistent decline in the net fixed asset turnover ratio reinforces a disconnect between asset growth and revenue generation, suggesting that the recent asset increases have not yet translated into proportional revenue increases. This may point to inefficiencies in asset utilization or a strategic shift involving long-term capital investment without immediate revenue effects.
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Cytokinetics Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Property and equipment, net | |||||||||||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||||||||||
| Property and equipment, net (including operating lease, right-of-use asset) | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset)
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Property and equipment, net (including operating lease, right-of-use asset)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several important trends and shifts over the observed periods:
- Revenues
- The revenue figures demonstrate significant volatility and irregularity across the quarters. Initially, there is a declining trend from early 2019 through early 2020, decreasing from 8,464 thousand USD to 3,593 thousand USD. Following this decline, a remarkable spike occurs in the third quarter of 2020 with revenues soaring to 41,688 thousand USD, which is an outlier relative to preceding and subsequent quarters. Revenues then regress to lower figures but experience another dramatic increase towards the end of 2021 and mid-2022, peaking at 55,600 and later 88,968 thousand USD, respectively. However, the final quarters of the data set show a downward return to modest values below 5,000 thousand USD, indicating episodes of both substantial growth and decline without a consistent upward or downward trajectory.
- Property and Equipment, Net
- This asset category shows a consistent and pronounced upward trend across all quarters. Starting at 3,175 thousand USD in early 2019, the net value steadily increases to 163,190 thousand USD by the end of 2022, before a slight decline in 2023 toward approximately 155,543 thousand USD. The steady growth in property and equipment suggests continued capital investment or asset accumulation over the period, contributing to an expanding asset base.
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio indicates a declining efficiency in the use of fixed assets to generate revenue over the period. Beginning at a high ratio of approximately 10.93 in early 2019, the ratio consistently falls, with minor short-lived recoveries, reaching as low as 0.05 by the latest reported period. This decreasing trend implies that revenue generated per dollar of fixed assets is diminishing, potentially signaling underutilization of assets or a lag in revenue growth relative to asset expansion.
In summary, while property and equipment have substantially increased, revenue figures are irregular with episodic spikes followed by declines, and the efficiency measure of asset utilization has markedly decreased. This pattern may indicate challenges in converting asset investment into stable, proportionate revenue while reflecting a period of substantial capital deployment or asset accumulation amid fluctuating revenue performance.
Total Asset Turnover
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Total asset turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Total Asset Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Total asset turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the analyzed periods. Revenues exhibit significant volatility with a general downward trend in recent quarters. Initially, revenues fluctuate between approximately $3.8 million and over $41 million, with some spikes reaching up to nearly $56 million, but more recently they decline sharply to below $1 million. This indicates episodic revenue generation possibly linked to specific events or product cycles rather than consistent sales growth.
Total assets demonstrate a rising trend through much of the period, starting around $198 million and peaking near $1.08 billion before declining moderately towards the end. This growth in assets suggests substantial investment or capital accumulation over time. However, the slight reduction in total assets in the latest quarters may imply asset sales, depreciation, or strategic shifts in asset management.
Total asset turnover is relatively low throughout, generally remaining below 0.2. This low ratio indicates that asset utilization to generate revenue is limited. The turnover ratio decreases significantly in some quarters to as low as 0.01, indicating inefficiency in converting assets into sales during those periods. Occasional increases in asset turnover, such as toward the middle of the dataset, suggest temporary improvements in efficiency but these are not sustained.
- Revenue Trends
- Revenues display high variability with peaks corresponding to certain quarters, followed by sharp declines. The recent consistent downward pattern suggests challenges in generating steady revenue streams.
- Total Assets
- Assets increase markedly over the majority of the timeframe, reflecting growing investment or acquisition of assets, followed by a moderate decline in the latest periods.
- Total Asset Turnover
- The ratio remains consistently low, underlining limited efficiency in asset use for revenue generation, with notable drops indicating even poorer utilization in some quarters.
Overall, the data suggests a company managing significant asset growth but struggling with consistent revenue generation and efficient asset utilization. The volatility and downward trend in revenues alongside low turnover ratios may warrant further investigation into operational efficiency and revenue drivers.
Equity Turnover
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Stockholders’ equity (deficit) | |||||||||||||||||||||||||
| Long-term Activity Ratio | |||||||||||||||||||||||||
| Equity turnover1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Equity Turnover, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Equity turnover
= (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the observed periods. Revenues display significant volatility, with a general pattern of decline followed by sharp spikes and subsequent decreases. Early periods show a descending trend from 8,464 thousand US dollars in the first quarter of 2019 down to 3,593 thousand by the second quarter of 2020. This is interrupted by an extraordinary increase to 41,688 thousand in the third quarter of 2020, followed by fluctuations and another sharp rise to 55,600 thousand in the fourth quarter of 2021. Most recent quarters reflect substantially lower revenue figures, with values dropping to several hundred thousand US dollars by the third quarter of 2023.
Stockholders’ equity (deficit) experiences drastic fluctuations across the periods, indicating significant financial instability or restructuring activities. Starting at a positive 3,372 thousand US dollars at the beginning of 2019, equity turns negative by the second quarter of 2019 and worsens to nearly -78,080 thousand by mid-2020. A sharp reversal occurs in the later quarters of 2020, with equity jumping to a positive 149,605 thousand and peaking at 249,020 thousand by the third quarter of 2021. However, from this peak, a downward trend is evident, with equity deteriorating progressively into negative territory again, reaching approximately -438,801 thousand by the third quarter of 2023.
Equity turnover ratios, although sporadically reported, show considerable variation. The limited available data indicate an initial high ratio of 10.29 in the first quarter of 2019, a notable dip to 0.36 in the third quarter of 2020, and some recovery to values up to 3.51 by late 2021. Post-2021, equity turnover data is incomplete, limiting comprehensive analysis, though the figures suggest fluctuating efficiency in utilizing equity to generate revenues.
Overall, the data suggests an unstable financial performance marked by large swings in revenue and equity. The extreme variations in stockholders’ equity imply significant capital structure changes or extraordinary transactions. Revenue volatility, coupled with inconsistent equity turnover figures, may point to challenges in maintaining consistent operational performance and capital utilization over the periods observed.
- Revenues
- Display high volatility with extreme spikes and subsequent declines.
- Significant peaks in Q3 2020 and Q4 2021 suggest episodic events improving income temporarily.
- Recent quarters show a stark decrease, possibly indicating reduced business activity.
- Stockholders’ Equity (Deficit)
- Shows dramatic fluctuations between positive and negative values, signaling financial instability.
- Sharp rise in equity from late 2020 through 2021 followed by a steep decline into deficit territory by 2023.
- Suggests major restructuring, financing activities, or valuation adjustments.
- Equity Turnover Ratio
- Data is limited but points to variable efficiency in equity utilization.
- High initial ratio followed by a dip, partial recoveries, and inconsistent reporting hinder clear trend identification.